Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. LoRusso PM, et al. Among authors: pilat mj. PLoS One. 2021 Apr 7;16(4):e0248097. doi: 10.1371/journal.pone.0248097. eCollection 2021. PLoS One. 2021. PMID: 33826614 Free PMC article. Clinical Trial.
Vascular targeting agents.
Pilat MJ, McCormick J, LoRusso PM. Pilat MJ, et al. Curr Oncol Rep. 2004 Mar;6(2):103-10. doi: 10.1007/s11912-004-0021-6. Curr Oncol Rep. 2004. PMID: 14751087 Review.
Vascular disrupting agents.
Pilat MJ, Lorusso PM. Pilat MJ, et al. J Cell Biochem. 2006 Nov 1;99(4):1021-39. doi: 10.1002/jcb.20783. J Cell Biochem. 2006. PMID: 16927308
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Lorusso P, Heath EI, McGreivy J, Sun YN, Melara R, Yan L, Malburg L, Ingram M, Wiezorek J, Chen L, Pilat MJ. Lorusso P, et al. Among authors: pilat mj. Invest New Drugs. 2008 Oct;26(5):455-62. doi: 10.1007/s10637-008-9144-1. Epub 2008 Jun 24. Invest New Drugs. 2008. PMID: 18574557 Clinical Trial.
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
LoRusso P, Shapiro GI, Hurwitz H, Pilat MJ, Chemidlin J, Kollia G, Syed S, Fischer B, Masson E. LoRusso P, et al. Among authors: pilat mj. Cancer Chemother Pharmacol. 2011 Dec;68(6):1377-85. doi: 10.1007/s00280-011-1603-2. Epub 2011 Apr 3. Cancer Chemother Pharmacol. 2011. PMID: 21461891 Clinical Trial.
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.
LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM. LoRusso PM, et al. Among authors: pilat mj. Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10. Mol Cancer Ther. 2015. PMID: 26063764 Free PMC article. Clinical Trial.
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI. LoRusso PM, et al. Among authors: pilat mj. Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3. Clin Cancer Res. 2016. PMID: 26842236 Free PMC article. Clinical Trial.
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM. Goncalves PH, et al. Among authors: pilat mj. Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464. Oncotarget. 2017. PMID: 28415633 Free PMC article. Clinical Trial.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI, LoRusso P, Kwak E, Pandya S, Rudin CM, Kurkjian C, Cleary JM, Pilat MJ, Jones S, de Crespigny A, Fredrickson J, Musib L, Yan Y, Wongchenko M, Hsieh HJ, Gates MR, Chan IT, Bendell J. Shapiro GI, et al. Among authors: pilat mj. Invest New Drugs. 2020 Apr;38(2):419-432. doi: 10.1007/s10637-019-00776-6. Epub 2019 Apr 24. Invest New Drugs. 2020. PMID: 31020608 Clinical Trial.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Fanucci K, et al. Among authors: pilat mj. Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36968138 Free PMC article. Clinical Trial.
38 results